FDA Warns “Do Not Use” Cardinal Health Monoject Syringes With Syringe Pumps and PCA Pumps

Warning comes after Cardinal Health recalled more than 32 million syringes in September, because they may not fit correctly into certain pain management drug pumps.

Doctors and healthcare facilities are being urged not to use Cardinal Health Monoject syringes with patient-controlled analgesia (PCA) pain management pumps, because they may be incompatible and not fit properly.

The U.S. Food and Drug Administration (FDA) issued the Cardinal Health Monoject syringe “Do Not Use” warning on November 20, due to a risk that use of the Monoject syringes with certain pain management pumps may cause the medications to not be administered properly, leading to potentially serious side effects for patients.

While the agency continues to evaluate the problems, doctors are being told to avoid using the syringes in combination with the PCA pumps.

Monoject Syringe and PCA Pump Compatibility Problems

Monoject syringes are used to inject and withdraw medications and fluids into or from the body. This can include administering fluids like blood or painkillers. When used with PCA pain pumps, the syringes are loaded with fluid or medications and placed directly into the pump.

In June 2023, Cardinal Health began distributing new Monoject syringes, replacing those original sold under the Covidien brand name. However, the new syringes have different dimensions, which has been linked to problems connecting them with PCA pain pumps.

If the syringe does not fit the pump properly, the device may have problems recognizing the syringes. This can lead to overdose, underdose, delays in therapy, delays in alarms, compatibility issues, and performance issues.

The FDA has received at least 15 reports of delayed therapy because of PCA pumps not recognizing the syringes and 13 reports of inaccurate dispensing, which also involved injuries. There were no reports of patient deaths.

In September, Cardinal Health issued a Monoject syringe recall for those devices with Luer-lock tips. The recall, which affected more than 32 million syringes, was given a Class I recall designation, after the FDA determined they posed a serious injury or death risk to users. The recall was conducted as a product correction, not as a product removal.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

FDA Continues to Investigate Monoject Problems

The FDA indicated the compatibility issues will be investigated further to find out if the issues affect other brands or other sizes of Monoject syringes. The FDA is working with the manufacturer to address the concerns.

The agency notes that facilities can continue using the older Covidien Monoject syringes with syringe pumps or PCA pumps, but it is important to note both brands of syringes have the “monoject” indicator on the syringe and do not include the company name. Only the outer packaging contains the Covidien brand name and will indicate if it is for a PCA pump.

FDA officials encourages patients and health care professionals to report problems and side effects experienced with the use of Cardinal Health Monoject syringes to the FDA’s MedWatch Adverse Event Reporting Program.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

EU Launches Investigation Into Ozempic Vision Loss Problems
EU Launches Investigation Into Ozempic Vision Loss Problems (Posted 3 days ago)

Following nearly 20 reports of vision problems from Ozempic or Wegovy since a study was published in July 2024, Danish health officials are calling for an EU investigation into the safety of semaglutide-based drugs.